Comment
. 2010 Apr;11(4):313-4; author reply 314.
doi: 10.1016/S1470-2045(10)70019-X.
Cetuximab in metastatic colorectal cancer
- PMID: 20359660
- DOI: 10.1016/S1470-2045(10)70019-X
Item in Clipboard
Comment
Cetuximab in metastatic colorectal cancer
Lancet Oncol.
2010 Apr.
No abstract available
Comment on
-
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26. Lancet Oncol. 2010. PMID: 19942479 Clinical Trial.
Similar articles
-
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195. J Clin Oncol. 2008. PMID: 18487581 No abstract available.
-
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.Clin Cancer Res. 2009 Jul 1;15(13):4508-13. doi: 10.1158/1078-0432.CCR-08-3179. Epub 2009 Jun 23. Clin Cancer Res. 2009. PMID: 19549774
-
Treatment of metastatic colon cancer: "the times they are A-changing".J Clin Oncol. 2013 Jun 1;31(16):1913-6. doi: 10.1200/JCO.2013.49.4500. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630214 No abstract available.
-
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.Cancer J. 2009 Mar-Apr;15(2):110-3. doi: 10.1097/PPO.0b013e31819e3202. Cancer J. 2009. PMID: 19390304 Review.
-
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100961 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
